Back to Search Start Over

Liquid Biopsies in Solid Cancers: Implementation in a Nordic Healthcare System

Authors :
Oddmund Nordgård
Bjørnar Gilje
Liv Cecilie Vestrheim Thomsen
Bjørn Henning Grønberg
Kjersti Tjensvoll
Reidun K. Kopperud
Karl-Henning Kalland
Rakel Brendsdal Forthun
Bjørn Tore Gjertsen
Morten Lapin
Randi Hovland
Source :
Cancers, Cancers, Vol 13, Iss 1861, p 1861 (2021)
Publication Year :
2021
Publisher :
MDPI AG, 2021.

Abstract

Simple Summary We here review liquid biopsy methods and their use in the diagnostics and treatment of patients with solid cancers. More specifically, circulating tumor DNA, circulating tumor cells, and their current and future clinical applications are considered. Important factors for further integration of liquid biopsy methods in clinical practice are discussed, with a special focus on a Nordic Healthcare system. Abstract Liquid biopsies have emerged as a potential new diagnostic tool, providing detailed information relevant for characterization and treatment of solid cancers. We here present an overview of current evidence supporting the clinical relevance of liquid biopsy assessments. We also discuss the implementation of liquid biopsies in clinical studies and their current and future clinical role, with a special reference to the Nordic healthcare systems. Our considerations are restricted to the most established liquid biopsy specimens: circulating tumor DNA (ctDNA) and circulating tumor cells (CTC). Both ctDNA and CTCs have been used for prognostic stratification, treatment choices, and treatment monitoring in solid cancers. Several recent publications also support the role of ctDNA in early cancer detection. ctDNA seems to provide more robust clinically relevant information in general, whereas CTCs have the potential to answer more basic questions related to cancer biology and metastasis. Epidermal growth factor receptor-directed treatment of non-small-cell lung cancer represents a clinical setting where ctDNA already has entered the clinic. The role of liquid biopsies in treatment decisions, standardization of methods, diagnostic performance and the need for further research, as well as cost and regulatory issues were identified as factors that influence further integration in the clinic. In conclusion, substantial evidence supports the clinical utility of liquid biopsies in cancer diagnostics, but further research is still required for a more general application in clinical practice.

Details

ISSN :
20726694
Volume :
13
Database :
OpenAIRE
Journal :
Cancers
Accession number :
edsair.doi.dedup.....393c32bda3e622daa430a8e342e78cd2